A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in 13-valent Pneumococcal Vaccine, Premature Birth and Immunization, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 42 Days to 98 Days. Per ClinicalTrials.gov, last updated 2017-05-11.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Premature Birth with a site in Poland — 3 open to participants now, 3 under way, none of them phase 3. Premature Birth · Poland.
Among the 23 studies in Premature Birth with a site in Poland, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2010, is the only one in phase 4, and was the 3rd registered.
2,554 studies on the registry are indexed under Premature Birth; 503 are open to participants now.
Browse Premature Birth studies →3 of the 23 studies in Premature Birth with a site in Poland are open now. Recruiting first, the newest first:
Leiden University Medical Center · Sites in Poland, Austria, Belgium and 16 more countries
Ages up to 32 wk
Polish Mother Memorial Hospital Research Institute · Sites in Poland
Ages 28 wk–32 wk
Polish Mother Memorial Hospital Research Institute · Sites in Poland
Ages up to 30 wk
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 315 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 223 (71%) stop at 75 or younger; 241 take children under 18; 105 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 53 across the 16 interventional studies, 200 across the 7 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Premature Birth with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the safety, tolerability, and immunogenicity of a 2,3,4 and 12 month schedule of the 13-valent pneumococcal conjugate vaccine when given to preterm infants with concomitant vaccines, compared to infants born at term.There will be a follow-up phase to assess the persistence of the antibody response at 24 and 36 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infant born at \< 37 weeks of gestation.
Biological: 13-valent pneumococcal conjugate vaccine
Infants born at ≥ 37 weeks of gestation
Biological: 13-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series
Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 1 Infant Series
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 1 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 2 Infant Series
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 2 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 3 Infant Series
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 3 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Toddler Dose
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after the toddler dose
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 1 Infant Series
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 1 of the infant series
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 2 Infant Series
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 2 of the infant series
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 3 Infant Series
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 3 of the infant series
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Toddler Dose
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
Time frame: Within 7 days after the toddler dose
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Infant Series
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Dose 1 up to 1 month after Dose 3 (infant series)
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): After Infant Series
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: 1 Month after Dose 3 of the infant series up to toddler dose
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Toddler Dose
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Toddler dose up to 1 Month after toddler dose
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 1-Year Follow-up After Toddler Dose
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: 1 month after toddler dose up to 1-year follow-up
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 2-Year Follow-up After Toddler Dose
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: 1-year follow-up after toddler dose to 2-year follow-up after toddler dose
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Toddler Pre-Dose to 1 Month After Toddler Dose
GMFR for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) from before 13vPnC toddler dose to 1 month after 13vPnC toddler dose were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC toddler dose and after 13vPnC toddler dose blood draws.
Time frame: Before 13vPnC Toddler Dose (pre-vaccination), 1 month after 13vPnC Toddler Dose
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After Infant Series: Group 1A, 1B, 1C
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 % CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 Month After Infant Series
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG antibody concentration to the given serotype for each arm, respectively.
Time frame: 1 month after the toddler dose
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level >=0.35 mcg/mL 1 Month After Toddler Dose: Group 1A, 1B, 1C
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Before Toddler Dose (pre-vaccination)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 Month After Toddler Dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 Year After Toddler Dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 2 Years After Toddler Dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Infant Series: Group 1A, 1B, 1C
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 Month After Infant Series
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose: Group 1A, 1B, 1C
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: Before Toddler Dose (pre-vaccination)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose: Group 1A, 1B, 1C
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 Month After Toddler Dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose: Group 1A, 1B, 1C
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 Year After Toddler Dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose: Group 1A, 1B, 1C
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 2 Years After Toddler Dose
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Infant Series
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: 1 Month After Infant Series
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Before Toddler Dose
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: Before the toddler dose (pre-vaccination)
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Toddler Dose
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: 1 Month After Toddler Dose
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Year After Toddler Dose
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: 1 Year After Toddler Dose
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 2 Years After Toddler Dose
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: 2 Years After Toddler Dose
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
Time frame: 1 Month After Infant Series
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) Before Toddler Dose
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
Time frame: Before Toddler Dose (pre-vaccination)
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Toddler Dose
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
Time frame: 1 Month After Toddler Dose
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Year After Toddler Dose
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
Time frame: 1 Year After Toddler Dose
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 2 Years After Toddler Dose
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
Time frame: 2 Years After Toddler Dose
| Milestone | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Started | 100 | 100 |
| Completed | 100 | 100 |
| Not completed | 0 | 0 |
| Milestone | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Started | 100 | 100 |
| Completed | 99 | 97 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: No longer met eligibility criteria | 0 | 1 |
| Milestone | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Started | 99 | 97 |
| Completed | 99 | 97 |
| Not completed | 0 | 0 |
| Milestone | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Started | 99 | 97 |
| Completed | 88 | 88 |
| Not completed | 11 | 9 |
| Withdrew: No longer willing to participate | 7 | 9 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Milestone | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Started | 88 | 88 |
| Completed | 81 | 80 |
| Not completed | 7 | 8 |
| Withdrew: No longer willing to participate | 5 | 6 |
| Withdrew: No longer met eligibility criteria | 2 | 2 |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n=99, 97) | 96.97 (91.40 to 99.37) | 98.97 (94.39 to 99.97) |
| 6B (n=99, 97) | 72.73 (62.85 to 81.20) | 87.63 (79.39 to 93.44) |
| 9V (n=99, 97) | 96.97 (91.40 to 99.37) | 96.91 (91.23 to 99.36) |
| 14 (n=99, 97) | 100.00 (96.34 to 100.00) | 97.94 (92.75 to 99.75) |
| 18C (n=99, 97) | 96.97 (91.40 to 99.37) | 94.85 (88.38 to 98.31) |
| 19F (n=99, 97) | 98.99 (94.50 to 99.97) | 98.97 (94.39 to 99.97) |
| 23F (n=99, 97 ) | 85.86 (77.41 to 92.05) | 92.78 (85.70 to 97.05) |
| 1 (n=99, 97) | 93.94 (87.27 to 97.74) | 95.88 (89.78 to 98.87) |
| 3 (n=99, 97) | 85.86 (77.41 to 92.05) | 90.72 (83.12 to 95.67) |
| 5 (n=99, 97) | 71.72 (61.78 to 80.31) | 90.72 (83.12 to 95.67) |
| 6A (n=98, 97) | 82.65 (73.69 to 89.56) | 94.85 (88.38 to 98.31) |
| 7F (n=99, 97) | 98.99 (94.50 to 99.97) | 98.97 (94.39 to 99.97) |
| 19A (n=99, 97) | 98.99 (94.50 to 99.97) | 98.97 (94.39 to 99.97) |
Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n=99, 97) | 1.96 (1.67 to 2.31) | 2.46 (2.04 to 2.97) |
| 6B (n=99, 97) | 0.73 (0.55 to 0.97) | 1.30 (1.00 to 1.67) |
| 9V (n=99, 97) | 1.26 (1.08 to 1.47) | 1.70 (1.45 to 2.00) |
| 14 (n=99, 97) | 7.48 (6.23 to 8.99) | 6.08 (4.82 to 7.67) |
| 18C (n=99, 97) | 1.93 (1.66 to 2.24) | 1.93 (1.62 to 2.29) |
| 19F (n=99, 97) | 2.21 (1.89 to 2.58) | 3.05 (2.62 to 3.55) |
| 23F (n=99, 97) | 0.86 (0.69 to 1.07) | 1.36 (1.10 to 1.68) |
| 1 (n=99, 97) | 1.26 (1.06 to 1.48) | 1.79 (1.50 to 2.13) |
| 3 (n=99, 97) | 0.83 (0.70 to 0.98) | 0.86 (0.75 to 1.00) |
| 5 (n=99, 97) | 0.56 (0.44 to 0.70) | 1.03 (0.87 to 1.22) |
| 6A (n=98, 97) | 1.22 (0.98 to 1.53) | 2.01 (1.65 to 2.46) |
| 7F (n=99, 97) | 2.14 (1.81 to 2.53) | 3.02 (2.63 to 3.48) |
| 19A (n=99, 97) | 2.85 (2.44 to 3.33) | 3.35 (2.85 to 3.94) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Tenderness- Any (n=94, 88) | 48.9 | 42.0 |
| Tenderness- Mild (n=93, 88) | 46.2 | 31.8 |
| Tenderness- Moderate (n=90, 85) | 17.8 | 16.5 |
| Tenderness- Severe (n=86, 85) | 0.0 | 0.0 |
| Swelling- Any (n=94, 89) | 39.4 | 29.2 |
| Swelling- Mild (n=91, 89) | 37.4 | 28.1 |
| Swelling- Moderate (n=91, 85) | 8.8 | 8.2 |
| Swelling- Severe (n=86, 85) | 0.0 | 0.0 |
| Redness- Any (n=92, 87) | 33.7 | 29.9 |
| Redness- Mild (n=90, 87) | 32.2 | 28.7 |
| Redness- Moderate (n=88, 85) | 3.4 | 4.7 |
| Redness- Severe (n=86, 85) | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Tenderness- Any (n=85, 88 ) | 48.2 | 38.6 |
| Tenderness- Mild (n=85, 84) | 43.5 | 31.0 |
| Tenderness- Moderate (n=77, 83) | 14.3 | 15.7 |
| Tenderness- Severe (n=73, 77) | 0.0 | 1.3 |
| Swelling- Any (n=84, 82) | 35.7 | 42.7 |
| Swelling- Mild (n=83, 82) | 33.7 | 42.7 |
| Swelling- Moderate (n=75, 76) | 8.0 | 2.6 |
| Swelling- Severe (n=73, 76) | 0.0 | 0.0 |
| Redness- Any (n=82, 82) | 28.0 | 40.2 |
| Redness- Mild (n=82, 82) | 28.0 | 37.8 |
| Redness- Moderate (n=73, 76) | 2.7 | 2.6 |
| Redness- Severe (n=73, 76) | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Tenderness- Any (n=82, 84) | 39.0 | 28.6 |
| Tenderness- Mild (n=81, 84) | 35.8 | 26.2 |
| Tenderness- Moderate (n=75, 78) | 9.3 | 5.1 |
| Tenderness- Severe (n=73, 77) | 0.0 | 0.0 |
| Swelling- Any (n=83, 85) | 30.1 | 41.2 |
| Swelling- Mild (n=82, 85) | 26.8 | 41.2 |
| Swelling- Moderate (n=75, 79) | 5.3 | 5.1 |
| Swelling- Severe (n=73, 77) | 0.0 | 0.0 |
| Redness- Any (n=82, 87) | 32.9 | 46.0 |
| Redness- Mild (n=82, 87) | 32.9 | 46.0 |
| Redness- Moderate (n=74, 79) | 1.4 | 3.8 |
| Redness- Severe (n=73, 77) | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Tenderness- Any (n=86, 85) | 69.8 | 55.3 |
| Tenderness- Mild (n=86, 85) | 66.3 | 51.8 |
| Tenderness- Moderate (n=77, 70) | 20.8 | 11.4 |
| Tenderness- Severe (n=74, 69) | 2.7 | 0.0 |
| Swelling- Any (n=81, 80) | 43.2 | 35.0 |
| Swelling- Mild (n=80, 79) | 38.8 | 32.9 |
| Swelling- Moderate (n=76, 74) | 13.2 | 9.5 |
| Swelling- Severe (n=74, 69) | 1.4 | 0.0 |
| Redness- Any (n=85, 83) | 51.8 | 49.4 |
| Redness- Mild (n=85, 83) | 51.8 | 48.2 |
| Redness- Moderate (n=75, 75) | 6.7 | 10.7 |
| Redness- Severe (n=74, 69) | 0.0 | 0.0 |
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Fever >=38 degrees C (n=86, 88) | 11.6 | 13.6 |
| Fever >=38 degrees C, =<39 degrees C (n=86, 88) | 10.5 | 13.6 |
| Fever >=39 degrees C, =<40 degrees C (n=86, 85) | 1.2 | 0.0 |
| Fever >40 degrees C (n=86, 85) | 0.0 | 0.0 |
| Decreased Appetite- Any (n=92, 89) | 60.9 | 41.6 |
| Decreased Appetite- Mild (n=91, 88) | 54.9 | 35.2 |
| Decreased Appetite- Moderate (n=88, 87) | 20.5 | 17.2 |
| Decreased Appetite- Severe (n=86, 85) | 1.2 | 0.0 |
| Increased Sleep- Any (n=96, 95) | 67.7 | 69.5 |
| Increased Sleep- Mild (n=96, 93) | 60.4 | 61.3 |
| Increased Sleep- Moderate (n=87, 88) | 29.9 | 30.7 |
| Increased Sleep- Severe (n=86, 85) | 2.3 | 2.4 |
| Irritability or Decreased Sleep- Any (n=95, 97) | 84.2 | 82.5 |
| Irritability or Decreased Sleep- Mild (n=93, 95) | 77.4 | 69.5 |
| Irritability or Decreased Sleep-Moderate (n=92, 91 | 43.5 | 47.3 |
| Irritability or Decreased Sleep- Severe (n=86, 85) | 8.1 | 5.9 |
| Use of Antipyretic Medication (n=90, 90) | 24.4 | 24.4 |
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Fever >=38 degrees C (n=79, 79) | 27.8 | 31.6 |
| Fever >=38 degrees C, =<39 degrees C (n=79, 79) | 27.8 | 30.4 |
| Fever >=39 degrees C, =<40 degrees C (n=73, 76) | 0.0 | 1.3 |
| Fever >40 degrees C (n=73, 76) | 0.0 | 0.0 |
| Decreased Appetite- Any (n=89, 84) | 61.8 | 46.4 |
| Decreased Appetite- Mild (n=88, 84) | 55.7 | 41.7 |
| Decreased Appetite- Moderate (n=79, 78) | 25.3 | 19.2 |
| Decreased Appetite- Severe (n=73, 76) | 1.4 | 0.0 |
| Increased Sleep- Any (n=85, 89 ) | 74.1 | 64.0 |
| Increased Sleep- Mild (n=83, 88) | 69.9 | 59.1 |
| Increased Sleep- Moderate (n=78, 78) | 34.6 | 29.5 |
| Increased Sleep- Severe (n=73, 76) | 2.7 | 1.3 |
| Irritability or Decreased Sleep- Any (n=95, 95) | 89.5 | 77.9 |
| Irritability or Decreased Sleep- Mild (n=90, 92) | 81.1 | 71.7 |
| Irritability or Decreased Sleep-Moderate (n=85, 86 | 64.7 | 44.2 |
| Irritability or Decreased Sleep- Severe (n=74, 76) | 17.6 | 2.6 |
| Use of Antipyretic Medication (n=84, 83) | 48.8 | 45.8 |
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Fever >=38 degrees C (n=79, 81) | 27.8 | 30.9 |
| Fever >=38 degrees C, =<39 degrees C (n=78, 81) | 26.9 | 30.9 |
| Fever >=39 degrees C, =<40 degrees C (n=75, 78) | 1.3 | 2.6 |
| Fever >40 degrees C (n=74, 77) | 0.0 | 0.0 |
| Decreased Appetite- Any (n=82, 84) | 48.8 | 47.6 |
| Decreased Appetite- Mild (n=82, 84) | 36.6 | 46.4 |
| Decreased Appetite- Moderate (n=74, 79) | 17.6 | 16.5 |
| Decreased Appetite- Severe (n=74, 77) | 1.4 | 1.3 |
| Increased Sleep- Any (n=88, 88 ) | 52.3 | 58.0 |
| Increased Sleep- Mild (n=88, 87) | 48.9 | 51.7 |
| Increased Sleep- Moderate (n=77, 80) | 16.9 | 20.0 |
| Increased Sleep- Severe (n=73, 77) | 1.4 | 1.3 |
| Irritability or Decreased Sleep- Any (n=92, 95) | 79.3 | 81.1 |
| Irritability or Decreased Sleep- Mild (n=90, 91) | 72.2 | 74.7 |
| Irritability or Decreased Sleep-Moderate (n=80,87) | 33.8 | 35.6 |
| Irritability or Decreased Sleep- Severe (n=74, 78) | 6.8 | 6.4 |
| Use of Antipyretic Medication (n=84, 81) | 40.5 | 38.3 |
Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| Fever >=38 degrees C (n= 80, 78) | 28.8 | 43.6 |
| Fever >=38 degrees C, =<39 degrees C (n=80, 77) | 27.5 | 42.9 |
| Fever >=39 degrees C, =<40 degrees C (n=74, 71) | 1.4 | 4.2 |
| Fever >40 degrees C (n=74, 70) | 0.0 | 1.4 |
| Decreased Appetite- Any (n=87, 86) | 57.5 | 60.5 |
| Decreased Appetite- Mild (n=86, 84) | 50.0 | 56.0 |
| Decreased Appetite- Moderate (n=78, 73) | 25.6 | 23.3 |
| Decreased Appetite- Severe (n=75, 69) | 1.3 | 1.4 |
| Increased Sleep- Any (n=83, 86 ) | 57.8 | 65.1 |
| Increased Sleep- Mild (n=82, 84) | 53.7 | 59.5 |
| Increased Sleep- Moderate (n=76, 74) | 18.4 | 24.3 |
| Increased Sleep- Severe (n=74, 70) | 0.0 | 2.9 |
| Irritability or Decreased Sleep- Any (n=90, 91) | 84.4 | 80.2 |
| Irritability or Decreased Sleep- Mild (n=90, 89) | 74.4 | 76.4 |
| Irritability or Decreased Sleep-Moderate (n=78,80) | 44.9 | 45.0 |
| Irritability or Decreased Sleep- Severe (n=76, 69) | 6.6 | 4.3 |
| Use of Antipyretic Medication (n=82, 79) | 48.8 | 50.6 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| AEs | 59.0 | 55.0 |
| SAEs | 14.0 | 5.0 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| AEs | 18.0 | 15.0 |
| SAEs | 8.0 | 9.0 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| AEs | 31.3 | 26.8 |
| SAEs | 2.0 | 1.0 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| AEs | 15.2 | 8.2 |
| SAEs | 13.1 | 8.2 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| AEs | 8.0 | 10.2 |
| SAEs | 6.8 | 9.1 |
GMFR for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) from before 13vPnC toddler dose to 1 month after 13vPnC toddler dose were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC toddler dose and after 13vPnC toddler dose blood draws.
| fold rise | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 83, 85) | 8.14 (6.61 to 10.04) | 9.61 (7.77 to 11.88) |
| 6B (n=80, 85) | 9.46 (7.81 to 11.45) | 7.61 (6.31 to 9.18) |
| 9V (n=83, 85) | 5.85 (5.05 to 6.78) | 4.92 (4.22 to 5.74) |
| 14 (n=83, 85) | 4.50 (3.76 to 5.38) | 4.65 (3.82 to 5.65) |
| 18C (n=83, 85) | 7.36 (6.29 to 8.61) | 9.14 (7.61 to 10.98) |
| 19F (n=83, 85) | 10.82 (8.88 to 13.17) | 12.31 (9.77 to 15.51) |
| 23F (n=79, 83) | 10.11 (8.13 to 12.57) | 10.15 (8.32 to 12.39) |
| 1 (n=83, 85) | 8.41 (6.94 to 10.20) | 9.98 (8.18 to 12.17) |
| 3 (n=81, 84) | 7.61 (5.79 to 10.01) | 5.23 (4.22 to 6.49) |
| 5 (n=80, 85) | 3.47 (3.04 to 3.97) | 3.46 (2.93 to 4.09) |
| 6A (n=83, 85) | 10.52 (8.75 to 12.64) | 7.72 (6.18 to 9.65) |
| 7F (n=83, 85) | 5.81 (5.12 to 6.61) | 6.07 (5.16 to 7.13) |
| 19A (n=83, 85) | 6.45 (5.39 to 7.72) | 5.59 (4.53 to 6.90) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 % CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| percentage of participants | 13vPnC Group 1A | 13vPnC Group 1B | 13vPnC Group 1C |
|---|---|---|---|
| 4 (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 96.00 (86.29 to 99.51) | 96.00 (79.65 to 99.90) |
| 6B (n=24, 50, 25) | 79.17 (57.85 to 92.87) | 72.00 (57.51 to 83.77) | 68.00 (46.50 to 85.05) |
| 9V (n=24, 50, 25) | 95.83 (78.88 to 99.89) | 98.00 (89.35 to 99.95) | 96.00 (79.65 to 99.90) |
| 14 (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 100.00 (92.89 to 100.00) | 100.00 (86.28 to 100.00) |
| 18C (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 94.00 (83.45 to 98.75) | 100.00 (86.28 to 100.00) |
| 19F (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 98.00 (89.35 to 99.95) | 100.00 (86.28 to 100.00) |
| 23F (n=24, 50, 25) | 91.67 (73.00 to 98.97) | 80.00 (66.28 to 89.97) | 92.00 (73.97 to 99.02) |
| 1 (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 92.00 (80.77 to 97.78) | 92.00 (73.97 to 99.02) |
| 3 (n=24, 50, 25) | 87.50 (67.64 to 97.34) | 86.00 (73.26 to 94.18) | 84.00 (63.92 to 95.46) |
| 5 (n=24, 50, 25) | 79.17 (57.85 to 92.87) | 66.00 (51.23 to 78.79) | 76.00 (54.87 to 90.64) |
| 6A (n=24, 49, 25) | 95.83 (78.88 to 99.89) | 81.63 (67.98 to 91.24) | 72.00 (50.61 to 87.93) |
| 7F (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 98.00 (89.35 to 99.95) | 100.00 (86.28 to 100.00) |
| 19A (n=24, 50, 25) | 100.00 (85.75 to 100.00) | 98.00 (89.35 to 99.95) | 100.00 (86.28 to 100.00) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG antibody concentration to the given serotype for each arm, respectively.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 6B (n=86, 87) | 97.67 (91.85 to 99.72) | 100.00 (95.85 to 100.00) |
| 9V (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 14 (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 18C (n=86, 87) | 100.00 (95.80 to 100.00) | 98.85 (93.76 to 99.97) |
| 19F (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 23F (n=86, 87) | 98.84 (93.69 to 99.97) | 100.00 (95.85 to 100.00) |
| 1 (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 3 (n=85, 87) | 70.59 (59.71 to 79.98) | 79.31 (69.29 to 87.25) |
| 5 (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 6A (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 7F (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
| 19A (n=86, 87) | 100.00 (95.80 to 100.00) | 100.00 (95.85 to 100.00) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants.
| percentage of participants | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 6B (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 95.56 (84.85 to 99.46) | 100.00 (83.16 to 100.00) |
| 9V (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 14 (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 18C (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 19F (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 23F (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 97.78 (88.23 to 99.94) | 100.00 (83.16 to 100.00) |
| 1 (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 3 (n=21, 44, 20) | 95.24 (76.18 to 99.88) | 68.18 (52.42 to 81.39) | 50.00 (27.20 to 72.80) |
| 5 (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 6A (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 7F (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
| 19A (n=21, 45, 20) | 100.00 (83.89 to 100.00) | 100.00 (92.13 to 100.00) | 100.00 (83.16 to 100.00) |
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 85, 85) | 0.31 (0.26 to 0.37) | 0.41 (0.34 to 0.49) |
| 6B (n= 82, 85) | 0.48 (0.39 to 0.58) | 0.94 (0.79 to 1.11) |
| 9V (n= 85, 85) | 0.39 (0.33 to 0.46) | 0.62 (0.53 to 0.72) |
| 14 (n= 85, 85) | 2.02 (1.68 to 2.43) | 2.36 (1.94 to 2.87) |
| 18C (n=85, 85) | 0.32 (0.28 to 0.37) | 0.30 (0.26 to 0.36) |
| 19F (n=85, 85) | 0.68 (0.57 to 0.80) | 0.93 (0.79 to 1.10) |
| 23F (n=81, 83) | 0.24 (0.18 to 0.31) | 0.40 (0.33 to 0.48) |
| 1 (n=85, 85) | 0.39 (0.34 to 0.46) | 0.41 (0.35 to 0.48) |
| 3 (n=84, 84) | 0.07 (0.05 to 0.09) | 0.11 (0.09 to 0.14) |
| 5 (n=82, 85) | 0.74 (0.64 to 0.87) | 1.06 (0.90 to 1.26) |
| 6A (n=85, 85) | 0.54 (0.45 to 0.65) | 1.01 (0.82 to 1.24) |
| 7F (n=85, 85) | 0.72 (0.63 to 0.82) | 0.84 (0.73 to 0.96) |
| 19A (n=85, 85) | 0.86 (0.72 to 1.03) | 1.57 (1.27 to 1.92) |
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| mcg/mL | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 86, 87) | 2.57 (2.18 to 3.03) | 3.97 (3.32 to 4.74) |
| 6B (n=86, 87) | 4.42 (3.64 to 5.37) | 7.27 (6.09 to 8.68) |
| 9V (n=86, 87) | 2.30 (1.99 to 2.66) | 3.06 (2.62 to 3.56) |
| 14 (n=86, 87) | 9.24 (7.66 to 11.14) | 11.02 (9.44 to 12.86) |
| 18C (n=86, 87) | 2.37 (2.02 to 2.79) | 2.81 (2.32 to 3.40) |
| 19F (n=86, 87) | 7.38 (6.23 to 8.76) | 11.67 (9.47 to 14.36) |
| 23F (n=86, 87) | 2.45 (2.01 to 2.98) | 4.03 (3.36 to 4.85) |
| 1 (n=86, 87) | 3.32 (2.83 to 3.89) | 4.09 (3.42 to 4.89) |
| 3 (n=85, 87) | 0.52 (0.44 to 0.62) | 0.57 (0.49 to 0.65) |
| 5 (n=86, 87) | 2.63 (2.28 to 3.02) | 3.72 (3.19 to 4.33) |
| 6A (n=86, 87) | 5.64 (4.86 to 6.54) | 7.84 (6.59 to 9.33) |
| 7F (n=86, 87) | 4.25 (3.75 to 4.82) | 5.13 (4.48 to 5.87) |
| 19A (n=86, 87) | 5.57 (4.66 to 6.65) | 8.84 (7.45 to 10.48) |
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 80, 79) | 0.30 (0.25 to 0.36) | 0.37 (0.31 to 0.44) |
| 6B (n=80, 80) | 1.26 (1.02 to 1.57) | 2.01 (1.69 to 2.39) |
| 9V (n=80, 80) | 0.61 (0.48 to 0.78) | 0.98 (0.82 to 1.19) |
| 14 (n=79, 80) | 1.43 (1.15 to 1.78) | 1.73 (1.40 to 2.14) |
| 18C (n=80, 79) | 0.33 (0.27 to 0.41) | 0.66 (0.54 to 0.81) |
| 19F (n=80, 79) | 0.96 (0.80 to 1.15) | 1.78 (1.40 to 2.26) |
| 23F (n=79, 80) | 0.59 (0.47 to 0.74) | 1.24 (1.01 to 1.52) |
| 1 (n=78, 80) | 0.40 (0.35 to 0.46) | 0.53 (0.45 to 0.62) |
| 3 (n=78, 78) | 0.13 (0.10 to 0.17) | 0.22 (0.16 to 0.30) |
| 5 (n=79, 78) | 1.10 (0.91 to 1.32) | 1.63 (1.35 to 1.97) |
| 6A (n=80, 79) | 1.08 (0.89 to 1.32) | 1.59 (1.34 to 1.90) |
| 7F (n=79, 80) | 0.68 (0.59 to 0.80) | 0.83 (0.72 to 0.96) |
| 19A (n=80, 80) | 1.61 (1.22 to 2.12) | 3.16 (2.53 to 3.95) |
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n=70, 71) | 0.19 (0.16 to 0.23) | 0.24 (0.20 to 0.29) |
| 6B (n=70, 70) | 1.44 (1.13 to 1.85) | 2.70 (2.10 to 3.48) |
| 9V (n=71, 70) | 0.74 (0.58 to 0.94) | 0.99 (0.80 to 1.23) |
| 14 (n=70, 71) | 1.06 (0.78 to 1.43) | 1.37 (1.03 to 1.82) |
| 18C (n=69, 71) | 0.32 (0.24 to 0.42) | 0.57 (0.47 to 0.69) |
| 19F (n=71, 70) | 1.10 (0.83 to 1.46) | 2.43 (1.71 to 3.44) |
| 23F (n=71, 71) | 1.03 (0.77 to 1.38) | 1.83 (1.42 to 2.37) |
| 1 (n=70, 69) | 0.32 (0.26 to 0.38) | 0.39 (0.32 to 0.47) |
| 3 (n=65, 63) | 0.17 (0.12 to 0.25) | 0.27 (0.18 to 0.40) |
| 5 (n=69, 69) | 1.34 (1.07 to 1.68) | 1.97 (1.60 to 2.41) |
| 6A (n=71, 71) | 1.41 (1.09 to 1.82) | 2.10 (1.64 to 2.70) |
| 7F (n=71, 70) | 0.60 (0.50 to 0.71) | 0.67 (0.57 to 0.80) |
| 19A (n=71, 71) | 2.33 (1.76 to 3.10) | 4.36 (3.40 to 5.61) |
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| mcg/mL | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n=24, 50, 25) | 2.50 (1.92 to 3.24) | 1.86 (1.47 to 2.37) | 1.73 (1.20 to 2.49) |
| 6B (n=24, 50, 25) | 1.23 (0.74 to 2.07) | 0.61 (0.42 to 0.88) | 0.62 (0.30 to 1.31) |
| 9V (n=24, 50, 25) | 1.44 (1.02 to 2.03) | 1.25 (1.02 to 1.53) | 1.14 (0.78 to 1.65) |
| 14 (n=24, 50, 25) | 8.95 (6.44 to 12.42) | 7.13 (5.65 to 8.98) | 6.95 (4.20 to 11.50) |
| 18C (n=24, 50, 25) | 2.58 (1.97 to 3.37) | 1.78 (1.44 to 2.19) | 1.72 (1.22 to 2.43) |
| 19F (n=24, 50, 25) | 2.46 (1.77 to 3.43) | 2.06 (1.67 to 2.55) | 2.28 (1.61 to 3.24) |
| 23F (n=24, 50, 25) | 1.38 (0.84 to 2.27) | 0.65 (0.48 to 0.89) | 0.95 (0.66 to 1.35) |
| 1 (n=24, 50, 25) | 1.56 (1.12 to 2.18) | 1.21 (0.96 to 1.52) | 1.10 (0.75 to 1.60) |
| 3 (n=24, 50, 25) | 1.28 (0.86 to 1.90) | 0.75 (0.60 to 0.93) | 0.67 (0.49 to 0.91) |
| 5 (n=24, 50, 25) | 0.85 (0.57 to 1.28) | 0.50 (0.36 to 0.69) | 0.46 (0.26 to 0.82) |
| 6A (n=24, 49, 25) | 1.74 (1.19 to 2.55) | 1.15 (0.84 to 1.57) | 0.98 (0.59 to 1.65) |
| 7F (n=24, 50, 25) | 2.43 (1.56 to 3.77) | 1.99 (1.61 to 2.46) | 2.18 (1.55 to 3.06) |
| 19A (n=24, 50, 25) | 3.43 (2.52 to 4.67) | 2.60 (2.08 to 3.25) | 2.88 (2.06 to 4.02) |
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| mcg/mL | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n= 20, 44, 21) | 0.37 (0.27 to 0.50) | 0.28 (0.22 to 0.36) | 0.32 (0.22 to 0.46) |
| 6B (n= 20, 42, 20) | 0.59 (0.42 to 0.83) | 0.42 (0.31 to 0.56) | 0.49 (0.30 to 0.80) |
| 9V (n= 20, 44, 21) | 0.43 (0.30 to 0.60) | 0.36 (0.28 to 0.46) | 0.44 (0.33 to 0.60) |
| 14 (n=20, 44, 21) | 2.48 (1.74 to 3.54) | 1.83 (1.40 to 2.38) | 2.04 (1.33 to 3.12) |
| 18C (n=20, 44, 21) | 0.35 (0.25 to 0.48) | 0.30 (0.24 to 0.36) | 0.34 (0.24 to 0.49) |
| 19F (n=20, 44, 21) | 0.96 (0.57 to 1.61) | 0.58 (0.48 to 0.71) | 0.67 (0.52 to 0.87) |
| 23F (n=20, 41, 20) | 0.31 (0.19 to 0.52) | 0.21 (0.14 to 0.32) | 0.24 (0.14 to 0.41) |
| 1 (n=20, 44, 21) | 0.37 (0.27 to 0.52) | 0.39 (0.32 to 0.48) | 0.42 (0.30 to 0.61) |
| 3 (n=20, 44, 20) | 0.13 (0.07 to 0.24) | 0.06 (0.04 to 0.08) | 0.05 (0.02 to 0.09) |
| 5 (n=19, 43, 20) | 0.75 (0.56 to 1.01) | 0.71 (0.55 to 0.90) | 0.81 (0.62 to 1.06) |
| 6A (n=20, 44, 21) | 0.66 (0.46 to 0.93) | 0.49 (0.38 to 0.63) | 0.55 (0.35 to 0.85) |
| 7F (n=20, 44, 21) | 0.71 (0.55 to 0.92) | 0.64 (0.54 to 0.77) | 0.91 (0.69 to 1.19) |
| 19A (n=20, 44, 21) | 1.20 (0.76 to 1.89) | 0.72 (0.57 to 0.91) | 0.92 (0.66 to 1.30) |
Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| mcg/mL | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n= 21, 45, 20) | 3.58 (2.66 to 4.83) | 2.87 (2.29 to 3.59) | 1.41 (1.05 to 1.88) |
| 6B (n= 21, 45, 20) | 6.28 (4.60 to 8.58) | 4.28 (3.18 to 5.75) | 3.29 (2.24 to 4.84) |
| 9V (n= 21, 45, 20) | 2.99 (2.26 to 3.96) | 2.23 (1.81 to 2.74) | 1.88 (1.41 to 2.52) |
| 14 (n=21, 45, 20) | 13.20 (9.65 to 18.05) | 8.84 (6.58 to 11.90) | 7.01 (5.15 to 9.54) |
| 18C (n=21, 45, 20) | 3.71 (2.77 to 4.97) | 2.40 (1.95 to 2.96) | 1.45 (1.05 to 2.00) |
| 19F (n=21, 45, 20) | 10.45 (8.20 to 13.32) | 7.39 (5.62 to 9.71) | 5.12 (3.91 to 6.72) |
| 23F (n=21, 45, 20) | 3.57 (2.54 to 5.02) | 2.41 (1.80 to 3.21) | 1.71 (1.12 to 2.62) |
| 1 (n=21, 45, 20) | 4.78 (3.61 to 6.34) | 3.31 (2.62 to 4.18) | 2.28 (1.74 to 2.99) |
| 3 (n=21, 44, 20) | 0.88 (0.61 to 1.25) | 0.51 (0.41 to 0.64) | 0.31 (0.23 to 0.43) |
| 5 (n=21, 45, 20) | 3.41 (2.69 to 4.32) | 2.66 (2.14 to 3.30) | 1.95 (1.54 to 2.47) |
| 6A (n=21, 45, 20) | 6.95 (5.18 to 9.33) | 5.81 (4.68 to 7.22) | 4.23 (3.22 to 5.56) |
| 7F (n=21, 45, 20) | 5.29 (4.11 to 6.80) | 4.09 (3.41 to 4.89) | 3.69 (2.84 to 4.80) |
| 19A (n=21, 45, 20) | 8.63 (6.51 to 11.43) | 5.28 (3.96 to 7.04) | 3.96 (3.17 to 4.96) |
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n=18, 43, 19) | 0.30 (0.19 to 0.46) | 0.29 (0.23 to 0.37) | 0.32 (0.21 to 0.49) |
| 6B (n=18, 43, 19) | 1.49 (0.84 to 2.66) | 1.28 (0.96 to 1.70) | 1.06 (0.70 to 1.60) |
| 9V (n=18, 43, 19) | 0.59 (0.37 to 0.93) | 0.56 (0.42 to 0.75) | 0.80 (0.40 to 1.59) |
| 14 (n=18, 42, 19) | 1.37 (0.86 to 2.19) | 1.38 (1.09 to 1.75) | 1.62 (0.83 to 3.16) |
| 18C (n=18, 43, 19) | 0.39 (0.26 to 0.57) | 0.31 (0.24 to 0.41) | 0.32 (0.17 to 0.59) |
| 19F (n=18, 43, 19) | 1.27 (0.81 to 2.00) | 0.89 (0.70 to 1.14) | 0.86 (0.62 to 1.21) |
| 23F (n=18, 42, 19) | 0.79 (0.50 to 1.26) | 0.54 (0.40 to 0.74) | 0.53 (0.30 to 0.91) |
| 1 (n=18, 41, 19) | 0.39 (0.30 to 0.50) | 0.38 (0.32 to 0.47) | 0.45 (0.31 to 0.64) |
| 3 (n=18, 41, 19) | 0.17 (0.10 to 0.29) | 0.12 (0.09 to 0.17) | 0.11 (0.05 to 0.23) |
| 5 (n=18, 42, 19) | 0.87 (0.59 to 1.28) | 1.24 (0.93 to 1.64) | 1.05 (0.77 to 1.44) |
| 6A (n=18, 43, 19) | 1.17 (0.73 to 1.87) | 1.05 (0.80 to 1.40) | 1.07 (0.72 to 1.59) |
| 7F (n=18, 42, 19) | 0.65 (0.47 to 0.91) | 0.65 (0.52 to 0.81) | 0.81 (0.61 to 1.08) |
| 19A (n=18, 43, 19) | 2.12 (0.90 to 5.01) | 1.50 (1.05 to 2.14) | 1.45 (0.95 to 2.21) |
The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC (Group 1A) | 13vPnC (Group 1B) | 13vPnC (Group 1C) |
|---|---|---|---|
| 4 (n=17, 35, 18) | 0.17 (0.11 to 0.28) | 0.19 (0.16 to 0.24) | 0.21 (0.13 to 0.33) |
| 6B (n=17, 35, 18) | 1.39 (0.81 to 2.40) | 1.81 (1.28 to 2.56) | 0.96 (0.58 to 1.60) |
| 9V (n=17, 36, 18) | 0.68 (0.39 to 1.17) | 0.83 (0.59 to 1.16) | 0.63 (0.36 to 1.12) |
| 14 (n=17, 35, 18) | 1.27 (0.59 to 2.76) | 1.02 (0.71 to 1.48) | 0.96 (0.47 to 1.96) |
| 18C (n=16, 35, 18) | 0.34 (0.18 to 0.65) | 0.35 (0.23 to 0.52) | 0.26 (0.16 to 0.44) |
| 19F (n=17, 36, 18) | 1.53 (0.83 to 2.81) | 0.93 (0.68 to 1.28) | 1.13 (0.50 to 2.53) |
| 23F (n=17, 36, 18) | 1.14 (0.60 to 2.15) | 1.41 (0.95 to 2.09) | 0.50 (0.27 to 0.90) |
| 1 (n=17, 35, 18) | 0.32 (0.23 to 0.44) | 0.35 (0.26 to 0.47) | 0.26 (0.18 to 0.39) |
| 3 (n=16, 33, 16) | 0.20 (0.10 to 0.39) | 0.19 (0.11 to 0.30) | 0.14 (0.06 to 0.34) |
| 5 (n=17, 35, 17) | 1.18 (0.67 to 2.11) | 1.67 (1.25 to 2.25) | 0.97 (0.62 to 1.50) |
| 6A (n=17, 36, 18) | 1.32 (0.87 to 1.99) | 1.58 (1.10 to 2.26) | 1.20 (0.63 to 2.30) |
| 7F (n=17, 36, 18) | 0.61 (0.39 to 0.96) | 0.68 (0.54 to 0.84) | 0.46 (0.32 to 0.67) |
| 19A (n=17, 36, 18) | 3.04 (1.64 to 5.64) | 2.46 (1.69 to 3.58) | 1.64 (0.83 to 3.23) |
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n=58, 62) | 1231 (986.5 to 1537.3) | 923 (746.9 to 1139.7) |
| 6B (n=51, 61) | 835 (478.6 to 1455.2) | 732 (494.0 to 1086.0) |
| 9V (n=54, 60) | 151 (70.8 to 321.1) | 211 (108.2 to 413.4) |
| 14 (n=55, 66) | 1298 (968.3 to 1740.3) | 1033 (735.7 to 1451.0) |
| 18C (n=56, 63) | 2931 (2341.2 to 3669.3) | 2057 (1594.0 to 2655.1) |
| 19F (n= 55, 58) | 417 (330.7 to 525.8) | 335 (237.2 to 472.3) |
| 23F (n=55, 60) | 733 (539.3 to 997.3) | 582 (413.7 to 817.8) |
| 1 (n=88, 87) | 10 (8.0 to 13.4) | 13 (10.0 to 16.8) |
| 3 (n=83, 86) | 61 (51.2 to 73.2) | 57 (46.3 to 69.5) |
| 5 (n=83, 85) | 37 (25.9 to 53.9) | 64 (47.2 to 86.9) |
| 6A (n=88, 88) | 1566 (1312.3 to 1869.0) | 1287 (980.1 to 1691.1) |
| 7F (n=93, 86) | 1605 (1277.9 to 2014.7) | 1539 (1297.4 to 1826.3) |
| 19A (n=92, 86) | 283 (232.4 to 344.1) | 244 (204.1 to 290.6) |
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 56, 59) | 10 (6.0 to 15.3) | 13 (7.9 to 21.9) |
| 6B (n= 59, 62) | 12 (6.8 to 20.1) | 15 (8.5 to 25.6) |
| 9V (n=52, 63) | 11 (6.2 to 20.9) | 7 (4.9 to 11.1) |
| 14 (n= 60, 55) | 242 (148.5 to 394.0) | 389 (260.4 to 582.2) |
| 18C (n= 54, 58) | 32 (16.1 to 61.7) | 51 (26.8 to 98.3) |
| 19F (n= 57, 60) | 6 (4.1 to 7.4) | 4 (3.8 to 4.7) |
| 23F (n=59, 62) | 11 (6.9 to 19.0) | 16 (9.6 to 26.6) |
| 1 (n=76, 80) | 6 (4.5 to 6.8) | 4 (3.9 to 4.8) |
| 3 (n=73, 77) | 8 (6.2 to 10.0) | 8 (6.6 to 10.4) |
| 5 (n=74, 79) | 5 (4.2 to 6.0) | 5 (4.2 to 5.6) |
| 6A (n=69, 76) | 45 (25.2 to 81.1) | 91 (56.6 to 146.3) |
| 7F (n=75, 79) | 228 (137.6 to 377.1) | 188 (109.3 to 323.1) |
| 19A (n=77, 79) | 9 (6.3 to 12.0) | 10 (7.1 to 14.8) |
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 67, 61) | 1154 (879.2 to 1514.5) | 1757 (1329.1 to 2322.4) |
| 6B (n= 64, 61) | 1229 (877.2 to 1722.1) | 1406 (1003.4 to 1970.3) |
| 9V (n=60, 58) | 1871 (1217.8 to 2873.6) | 2542 (1711.6 to 3775.2) |
| 14 (n= 62, 62) | 1294 (969.0 to 1728.4) | 1651 (1300.1 to 2097.1) |
| 18C (n= 62, 63) | 2464 (1696.0 to 3579.4) | 4510 (3399.7 to 5981.7) |
| 19F (n= 61, 62) | 376 (229.1 to 617.1) | 640 (431.5 to 948.3) |
| 23F (n=65, 63) | 1048 (738.6 to 1488.0) | 1657 (1217.7 to 2255.0) |
| 1 (n=80, 83) | 59 (43.7 to 78.6) | 107 (83.0 to 137.0) |
| 3 (n=78, 79) | 114 (97.1 to 132.7) | 121 (103.4 to 140.4) |
| 5 (n=80, 83) | 166 (127.9 to 216.3) | 260 (203.9 to 331.9) |
| 6A (n=78, 74) | 1978 (1571.5 to 2489.7) | 3154 (2606.0 to 3816.0) |
| 7F (n=81, 82) | 2915 (2453.4 to 3462.7) | 3154 (2746.2 to 3622.4) |
| 19A (n=81, 82) | 558 (456.3 to 682.6) | 825 (692.4 to 983.8) |
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 66, 59) | 24 (12.9 to 45.5) | 29 (15.2 to 54.5) |
| 6B (n= 65, 59) | 38 (19.0 to 74.9) | 36 (19.2 to 68.8) |
| 9V (n=61, 63) | 141 (67.5 to 293.1) | 244 (126.3 to 469.7) |
| 14 (n= 59, 54) | 276 (169.0 to 449.4) | 372 (236.1 to 586.5) |
| 18C (n= 62, 60) | 33 (16.4 to 67.4) | 121 (56.9 to 258.1) |
| 19F (n= 67, 57) | 11 (6.2 to 17.7) | 18 (9.6 to 35.4) |
| 23F (n=67, 62) | 45 (23.7 to 86.6) | 168 (92.4 to 303.9) |
| 1 (n=76, 74) | 5 (4.2 to 6.3) | 5 (4.3 to 5.8) |
| 3 (n=76, 70) | 11 (8.6 to 15.4) | 13 (9.2 to 18.7) |
| 5 (n=72, 70) | 8 (5.6 to 10.4) | 10 (7.0 to 13.3) |
| 6A (n=70, 70) | 98 (53.0 to 183.0) | 255 (152.9 to 424.8) |
| 7F (n=71, 71) | 599 (411.0 to 873.3) | 533 (348.3 to 814.1) |
| 19A (n=74, 73) | 28 (17.2 to 43.9) | 54 (34.2 to 85.5) |
Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 46, 54) | 15 (7.0 to 32.9) | 17 (9.0 to 32.6) |
| 6B (n= 56, 48) | 29 (13.7 to 59.9) | 27 (12.4 to 58.2) |
| 9V (n=50, 55) | 132 (57.5 to 301.5) | 75 (34.7 to 163.7) |
| 14 (n= 49, 45) | 262 (142.0 to 482.8) | 296 (161.6 to 543.8) |
| 18C (n= 56, 56) | 14 (7.1 to 25.9) | 29 (14.3 to 57.9) |
| 19F (n= 60, 58) | 13 (7.4 to 22.5) | 20 (10.1 to 39.9) |
| 23F (n=58, 59) | 60 (29.7 to 122.2) | 135 (71.2 to 255.3) |
| 1 (n=70, 68) | 5 (4.1 to 5.4) | 4 (3.9 to 4.6) |
| 3 (n=69, 66) | 11 (8.1 to 15.2) | 16 (10.7 to 24.2) |
| 5 (n=68, 69) | 5 (4.1 to 5.6) | 7 (5.4 to 9.4) |
| 6A (n=68, 62) | 42 (21.5 to 81.1) | 102 (53.7 to 193.4) |
| 7F (n=64, 65) | 170 (87.7 to 330.9) | 269 (155.6 to 463.7) |
| 19A (n=68, 67) | 22 (13.6 to 37.1) | 50 (30.1 to 82.6) |
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 58, 62) | 100.00 (93.84 to 100.00) | 100.00 (94.22 to 100.00) |
| 6B (n= 51, 61) | 90.20 (78.59 to 96.74) | 95.08 (86.29 to 98.97) |
| 9V (n= 54, 60) | 64.81 (50.62 to 77.32) | 71.67 (58.56 to 82.55) |
| 14 (n= 55, 66) | 100.00 (93.51 to 100.00) | 96.97 (89.48 to 99.63) |
| 18C (n= 56, 63) | 100.00 (93.62 to 100.00) | 100.00 (94.31 to 100.00) |
| 19F (n= 55, 58) | 100.00 (93.51 to 100.00) | 96.55 (88.09 to 99.58) |
| 23F (n= 55, 60) | 98.18 (90.28 to 99.95) | 96.67 (88.47 to 99.59) |
| 1 (n= 88, 87) | 40.91 (30.54 to 51.91) | 51.72 (40.75 to 62.58) |
| 3 (n=83, 86) | 100.00 (95.65 to 100.00) | 95.35 (88.52 to 98.72) |
| 5 (n= 83, 85) | 67.47 (56.30 to 77.35) | 83.53 (73.91 to 90.69) |
| 6A (n= 88, 88) | 100.00 (95.89 to 100.00) | 97.73 (92.03 to 99.72) |
| 7F (n= 93, 86) | 97.85 (92.45 to 99.74) | 100.00 (95.80 to 100.00) |
| 19A (n= 92, 86) | 98.91 (94.09 to 99.97) | 100.00 (95.80 to 100.00) |
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n=56, 59) | 21.43 (11.59 to 34.44) | 30.51 (19.19 to 43.87) |
| 6B (n=59, 62) | 22.03 (12.29 to 34.73) | 27.42 (16.85 to 40.23) |
| 9V (n=52, 63) | 19.23 (9.63 to 32.53) | 12.70 (5.65 to 23.50) |
| 14 (n=60, 55) | 86.67 (75.41 to 94.06) | 94.55 (84.88 to 98.86) |
| 18C (n=54, 58) | 44.44 (30.92 to 58.60) | 55.17 (41.54 to 68.26) |
| 19F (n=57, 60) | 8.77 (2.91 to 19.30) | 1.67 (0.04 to 8.94) |
| 23F (n=59, 62) | 23.73 (13.62 to 36.59) | 37.10 (25.16 to 50.31) |
| 1 (n=76, 80) | 11.84 (5.56 to 21.29) | 3.75 (0.78 to 10.57) |
| 3 (n=73, 77) | 32.88 (22.33 to 44.87) | 40.26 (29.23 to 52.06) |
| 5 (n=74, 79) | 8.11 (3.03 to 16.82) | 7.59 (2.84 to 15.80) |
| 6A (n=69, 76) | 52.17 (39.80 to 64.35) | 72.37 (60.91 to 82.01) |
| 7F (n=75, 79) | 78.67 (67.68 to 87.29) | 73.42 (62.28 to 82.73) |
| 19A (n=77, 79) | 25.97 (16.64 to 37.23) | 29.11 (19.43 to 40.42) |
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 67, 61) | 100.00 (94.64 to 100.00) | 100.00 (94.13 to 100.00) |
| 6B (n= 64, 61) | 98.44 (91.60 to 99.96) | 98.36 (91.20 to 99.96) |
| 9V (n= 60, 58) | 95.00 (86.08 to 98.96) | 96.55 (88.09 to 99.58) |
| 14 (n= 62, 62) | 100.00 (94.22 to 100.00) | 100.00 (94.22 to 100.00) |
| 18C (n= 62, 63) | 98.39 (91.34 to 99.96) | 100.00 (94.31 to 100.00) |
| 19F (n= 61, 62) | 88.52 (77.78 to 95.26) | 95.16 (86.50 to 98.99) |
| 23F (n= 65, 63) | 98.46 (91.72 to 99.96) | 98.41 (91.47 to 99.96) |
| 1 (n= 80, 83) | 87.50 (78.21 to 93.84) | 93.98 (86.50 to 98.02) |
| 3 (n=78, 79) | 100.00 (95.38 to 100.00) | 98.73 (93.15 to 99.97) |
| 5 (n= 80, 83) | 96.25 (89.43 to 99.22) | 97.59 (91.57 to 99.71) |
| 6A (n=78, 74) | 100.00 (95.38 to 100.00) | 100.00 (95.14 to 100.00) |
| 7F (n= 81, 82) | 100.00 (95.55 to 100.00) | 100.00 (95.60 to 100.00) |
| 19A (n= 81, 82) | 100.00 (95.55 to 100.00) | 100.00 (95.60 to 100.00) |
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 66, 59) | 34.8 (23.5 to 47.6) | 42.4 (29.6 to 55.9) |
| 6B (n= 65, 59) | 41.5 (29.4 to 54.4) | 47.5 (34.3 to 60.9) |
| 9V (n= 61, 63) | 62.3 (49.0 to 74.4) | 73.0 (60.3 to 83.4) |
| 14 (n= 59, 54) | 86.4 (75.0 to 94.0) | 90.7 (79.7 to 96.9) |
| 18C (n= 62, 60) | 38.7 (26.6 to 51.9) | 61.7 (48.2 to 73.9) |
| 19F (n= 67, 57) | 17.9 (9.6 to 29.2) | 29.8 (18.4 to 43.4) |
| 23F (n= 67, 62) | 49.3 (36.8 to 61.8) | 77.4 (65.0 to 87.1) |
| 1 (n= 76, 74) | 10.5 (4.7 to 19.7) | 10.8 (4.8 to 20.2) |
| 3 (n=76, 70) | 47.4 (35.8 to 59.2) | 48.6 (36.4 to 60.8) |
| 5 (n= 72, 70) | 20.8 (12.2 to 32.0) | 31.4 (20.9 to 43.6) |
| 6A (n=70, 70) | 62.9 (50.5 to 74.1) | 81.4 (70.3 to 89.7) |
| 7F (n= 71, 71) | 93.0 (84.3 to 97.7) | 90.1 (80.7 to 95.9) |
| 19A (n= 74, 73) | 54.1 (42.1 to 65.7) | 72.6 (60.9 to 82.4) |
Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.
| percentage of participants | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) |
|---|---|---|
| 4 (n= 46, 54) | 21.7 (10.9 to 36.4) | 29.6 (18.0 to 43.6) |
| 6B (n= 56, 48) | 35.7 (23.4 to 49.6) | 35.4 (22.2 to 50.5) |
| 9V (n= 50, 55) | 60.0 (45.2 to 73.6) | 52.7 (38.8 to 66.3) |
| 14 (n= 49, 45) | 81.6 (68.0 to 91.2) | 84.4 (70.5 to 93.5) |
| 18C (n= 56, 56) | 21.4 (11.6 to 34.4) | 39.3 (26.5 to 53.2) |
| 19F (n= 60, 58) | 25.0 (14.7 to 37.9) | 29.3 (18.1 to 42.7) |
| 23F (n= 58, 59) | 53.4 (39.9 to 66.7) | 74.6 (61.6 to 85.0) |
| 1 (n= 70, 68) | 8.6 (3.2 to 17.7) | 2.9 (0.4 to 10.2) |
| 3 (n=69, 66) | 46.4 (34.3 to 58.8) | 51.5 (38.9 to 64.0) |
| 5 (n= 68, 69) | 7.4 (2.4 to 16.3) | 21.7 (12.7 to 33.3) |
| 6A (n=68, 62) | 44.1 (32.1 to 56.7) | 64.5 (51.3 to 76.3) |
| 7F (n= 64, 65) | 68.8 (55.9 to 79.8) | 80.0 (68.2 to 88.9) |
| 19A (n= 68, 67) | 45.6 (33.5 to 58.1) | 67.2 (54.6 to 78.2) |
Collected over AEs/SAEs: recorded from 13vPnC infant dose 1 to 2-year follow-up after toddler dose. Participants recorded pre-specified AEs in electronic diary: local reactions; systemic events (up to 7 days after each vaccine dose). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Group 1 (Preterm Infant) - Infant Series | — | 14/100 (14%) | 98/100 (98%) |
| 13vPnC Group 2 (Term Infant) - Infant Series | — | 5/100 (5%) | 99/100 (99%) |
| 13vPnC Group 1 (Preterm Infant) - After Infant Series | — | 8/100 (8%) | 13/100 (13%) |
| 13vPnC Group 2 (Term Infant) - After Infant Series | — | 9/100 (9%) | 11/100 (11%) |
| 13vPnC Group 1 (Preterm Infant) - Toddler Dose | — | 2/99 (2%) | 93/99 (93.9%) |
| 13vPnC Group 2 (Term Infant) - Toddler Dose | — | 1/97 (1%) | 92/97 (94.8%) |
| 13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up | — | 13/99 (13.1%) | 2/99 (2%) |
| 13vPnC Group 2 (Term Infant) - 1 Year Follow-up | — | 8/97 (8.2%) | 0/97 (0%) |
| 13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up | — | 6/88 (6.8%) | 1/88 (1.1%) |
| 13vPnC Group 2 (Term Infant) - 2 Year Follow-up | — | 8/88 (9.1%) | 1/88 (1.1%) |
| Event | 13vPnC Group 1 (Preterm Infant) - Infant Series | 13vPnC Group 2 (Term Infant) - Infant Series | 13vPnC Group 1 (Preterm Infant) - After Infant Series | 13vPnC Group 2 (Term Infant) - After Infant Series | 13vPnC Group 1 (Preterm Infant) - Toddler Dose | 13vPnC Group 2 (Term Infant) - Toddler Dose | 13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up | 13vPnC Group 2 (Term Infant) - 1 Year Follow-up | 13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up | 13vPnC Group 2 (Term Infant) - 2 Year Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 2/100 | 1/100 | 3/100 | 0/100 | 0/99 | 0/97 | 4/99 | 0/97 | 0/88 | 2/88 |
| BronchiolitisInfections and infestations | 4/100 | 2/100 | 1/100 | 0/100 | 1/99 | 0/97 | 1/99 | 0/97 | 0/88 | 0/88 |
| BronchopneumoniaInfections and infestations | 0/100 | 0/100 | 1/100 | 3/100 | 0/99 | 0/97 | 1/99 | 0/97 | 0/88 | 1/88 |
| Cerebral palsyCongenital, familial and genetic disorders | 0/100 | 0/100 | 0/100 | 0/100 | 0/99 | 0/97 | 0/99 | 0/97 | 2/88 | 0/88 |
| IntussusceptionGastrointestinal disorders | 0/100 | 0/100 | 0/100 | 0/100 | 0/99 | 0/97 | 0/99 | 2/97 | 0/88 | 0/88 |
| BronchitisInfections and infestations | 0/100 | 1/100 | 0/100 | 2/100 | 0/99 | 0/97 | 2/99 | 0/97 | 1/88 | 1/88 |
| Respiratory tract infectionInfections and infestations | 0/100 | 0/100 | 0/100 | 0/100 | 0/99 | 0/97 | 2/99 | 0/97 | 0/88 | 0/88 |
| Abdominal painGastrointestinal disorders | 2/100 | 0/100 | 0/100 | 0/100 | 0/99 | 0/97 | 0/99 | 0/97 | 0/88 | 0/88 |
| GastroenteritisInfections and infestations | 1/100 | 0/100 | 2/100 | 0/100 | 0/99 | 0/97 | 1/99 | 0/97 | 0/88 | 0/88 |
| Pneumonia respiratory syncytial viralInfections and infestations | 2/100 | 0/100 | 0/100 | 0/100 | 1/99 | 0/97 | 1/99 | 0/97 | 0/88 | 0/88 |
| Event | 13vPnC Group 1 (Preterm Infant) - Infant Series | 13vPnC Group 2 (Term Infant) - Infant Series | 13vPnC Group 1 (Preterm Infant) - After Infant Series | 13vPnC Group 2 (Term Infant) - After Infant Series | 13vPnC Group 1 (Preterm Infant) - Toddler Dose | 13vPnC Group 2 (Term Infant) - Toddler Dose | 13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up | 13vPnC Group 2 (Term Infant) - 1 Year Follow-up | 13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up | 13vPnC Group 2 (Term Infant) - 2 Year Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| Irritability or Decreased Sleep- AnyGeneral disorders | 85/95 | 74/95 | — | — | — | — | — | — | — | — |
| Irritability or Decreased Sleep- AnyGeneral disorders | 80/95 | 80/97 | — | — | 76/90 | 73/91 | — | — | — | — |
| Irritability or Decreased Sleep- MildGeneral disorders | 73/90 | 66/92 | — | — | — | — | — | — | — | — |
| Irritability or Decreased Sleep- AnyGeneral disorders | 73/92 | 77/95 | — | — | — | — | — | — | — | — |
| Irritability or Decreased Sleep- MildGeneral disorders | 72/93 | 66/95 | — | — | 67/90 | 68/89 | — | — | — | — |
| Irritability or Decreased Sleep- MildGeneral disorders | 65/90 | 68/91 | — | — | — | — | — | — | — | — |
| Increased Sleep- AnyGeneral disorders | 63/85 | 57/89 | — | — | — | — | — | — | — | — |
| Increased Sleep- MildGeneral disorders | 58/83 | 52/88 | — | — | — | — | — | — | — | — |
| Tenderness- AnySkin and subcutaneous tissue disorders | 46/94 | 37/88 | — | — | 60/86 | 47/85 | — | — | — | — |
| Increased Sleep- AnyGeneral disorders | 65/96 | 66/95 | — | — | 48/83 | 56/86 | — | — | — | — |
Safety Analysis set included all participants who received at least 1 dose of 13vPnC.
| Age, Continuous(months) | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) | Total |
|---|---|---|---|
| Mean | 1.8 ± 0.6 | 1.5 ± 0.5 | 1.7 ± 0.6 |
| Sex: Female, Male(Participants) | 13vPnC Group 1 (Preterm Infant) | 13vPnC Group 2 (Term Infant) | Total |
|---|---|---|---|
| Female | 48 | 55 | 103 |
| Male | 52 | 45 | 97 |
The record gives a start of Oct 2010, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine